RARA and acute promyelocytic leukemia: All-trans-retinoic-acid (ATRA) (Figure 2E), alone or in combination with arsenic trioxide (ATO; As2O3), is currently the frontline treatment for acute promyelocytic leukemia (APL) harbouring the PML-RARα gene rearrangement [118, 119].